major
compon
innat
immun
complement
system
also
directli
regul
lymphocyt
function
recent
studi
shed
import
insight
role
complement
receptor
antitumor
immun
clinic
observ
anim
studi
suggest
complement
signal
inhibit
antitumor
immun
report
tumor
circul
complement
level
posit
correl
tumor
size
poor
outcom
differ
type
cancer
neuroblastoma
colorect
lung
ovarian
cancer
chronic
lymphocyt
leukemia
carcinoma
digest
tract
extens
anim
studi
also
demonstr
complement
system
function
inhibit
antitumor
immun
mechanist
complement
may
inhibit
antitumor
immun
promot
recruit
myeloidderiv
suppressor
cell
mdsc
tumor
microenviron
tme
suppress
dendrit
cell
dc
nk
cell
activ
recent
studi
suggest
new
mechan
play
import
role
complement
signalingmedi
suppress
antitumor
immun
direct
inhibit
product
tumor
infiltr
lymphocyt
til
tme
summar
relev
find
propos
function
new
class
immun
checkpoint
receptor
target
cancer
immunotherapi
addit
mani
clinic
report
posit
correl
complement
level
tumor
size
poor
outcom
variou
human
cancer
review
pio
et
al
anim
studi
test
differ
tumor
type
differ
mous
model
also
show
complement
signal
pathway
exert
potent
inhibit
antitumor
immun
tabl
test
mous
tumor
model
includ
cervic
cancer
lewi
lung
cancer
rma
lymphoma
breast
cancer
melanoma
skin
cancer
colon
cancer
either
transplant
tumor
cell
spontan
develop
cancer
complement
signal
disrupt
anim
studi
use
genet
model
includ
mice
defici
inhibitor
complement
report
result
highli
consist
tumor
growth
suppress
complementmedi
signal
inhibit
remov
studi
underli
cellular
mechan
markiewski
colleagu
first
show
interact
promot
migrat
mdsc
tumor
enhanc
suppress
capac
tumorassoci
mdsc
regul
myeloid
suppressor
cell
tumor
complement
signal
also
observ
sever
studi
thu
major
immun
suppress
role
complement
signal
may
mediat
recruit
mdsc
tumor
addit
mdsc
innat
cell
popul
neutrophil
dc
nk
cell
also
involv
complementmedi
immun
suppress
antitumor
immun
complement
exhaust
use
cobra
venom
factor
nk
cell
greatli
increas
tumor
deplet
nk
cell
nullifi
enhanc
antitumor
activ
induc
cobra
venom
factor
treatment
although
complement
signal
modul
innat
immun
cell
activ
enhanc
antitumor
immun
exhibit
mice
follow
disrupt
complement
signal
lymphocyt
depend
effector
til
enhanc
mice
also
deplet
cell
genet
delet
antibodi
cell
diminish
enhanc
antitumor
immun
complement
signal
defici
model
studi
suggest
multipl
immun
suppress
mechan
induc
signal
tabl
three
small
cation
peptid
gener
complement
activ
term
anaphylatoxin
peptid
induc
chemotaxi
cell
activ
inflammatori
signal
bind
respect
gproteincoupl
receptor
gpcr
refer
model
anaphylatoxin
bind
cognit
receptor
propos
molecular
clone
immun
system
predominantli
distribut
leukocyt
myeloid
lineag
neutrophil
basophil
eosinophil
mast
cell
monocytesmacrophag
ligandreceptor
engag
induc
receptor
phosphoryl
lead
receptor
desensit
intern
activ
divers
downstream
signal
pathway
differ
cell
type
highli
express
neutrophil
induc
calcium
influx
respons
howev
inhibit
neutrophil
mobil
vivo
intestin
ischemiareperfus
model
mast
cell
activ
signal
pathway
subsequ
aktphosphoryl
well
map
kinas
promot
cytokin
express
human
monocytemacrophag
engag
togeth
tlr
signal
induc
secret
proinflammatori
cytokin
signal
modul
secret
inflammasom
activ
regul
atp
efflux
similar
abundantli
express
neutrophil
eosinophil
basophil
monocytesmacrophag
mast
cell
bind
caus
calcium
flux
well
activ
sever
compon
differ
signal
pathway
includ
kinas
phospholipas
c
phospholipas
mediat
activ
addit
similar
proinflammatori
function
also
chemotact
receptor
upon
engag
serv
chemoattract
monocyt
neutrophil
eosinophil
basophil
well
establish
complement
compon
receptor
express
myeloid
tumor
cell
also
lymphocyt
furthermor
endogen
local
produc
bind
cell
regul
cell
function
differenti
surviv
cytokin
product
interestingli
contrast
lack
express
peripher
cell
naiv
mice
receptor
strongli
upregul
til
mous
human
tumor
overal
til
doubl
posit
determin
sourc
complement
mediat
immun
suppress
til
chimer
mice
either
lymphocyt
host
cell
lack
use
tumorbear
host
cell
suffici
remov
complementmedi
suppress
antitumor
immun
suggest
autocrin
product
interact
activ
product
play
critic
role
suppress
effector
til
function
autocrin
complement
signal
inhibit
effector
cell
function
sever
clue
suggest
possibl
mechan
underli
signalingmedi
immun
checkpoint
function
complement
signal
may
inhibit
product
effector
lymphocyt
given
role
til
expans
immun
activ
function
antitumor
immun
see
discuss
next
section
first
shown
fraction
effector
express
peak
coronaviru
infect
cell
show
superior
ctl
activ
vivo
protect
chronic
infect
second
found
complement
pathway
relat
gene
enrich
cell
suggest
possibl
mutual
reciproc
regul
inde
report
tiger
mice
til
within
tumor
peripher
blood
readili
express
kwak
colleagu
also
observ
enhanc
express
lymphocyt
lung
tumorbear
mice
furthermor
antagonist
also
promot
product
til
well
vitro
activ
cell
importantli
enhanc
antitumor
immun
complementdefici
mice
wildtyp
mice
treat
antagonist
depend
deplet
gene
mice
complet
abolish
enhanc
antitumor
immun
melanoma
breast
cancer
tumorbear
mice
suppress
product
til
mediat
endogen
produc
complement
autocrin
interact
cell
inhibit
product
signal
redund
antagon
one
receptor
alon
promot
product
accordingli
antagon
singl
receptor
suppress
tumor
growth
antitumor
effect
depend
vivo
therefor
inhibit
antitumor
immun
suppress
product
til
respons
signal
repres
new
mechan
complementmedi
immun
supress
pleiotrop
cytokin
produc
mani
cell
popul
includ
limit
activ
cell
b
cell
macrophag
well
mast
cell
although
initi
identifi
cofactor
thymocyt
growth
cell
activ
recogn
regulatori
cytokin
due
antiinflammatori
function
impair
matur
dendrit
cell
macrophag
interf
upregul
costimulatori
molecul
mhcii
activ
dendrit
cell
macrophag
addit
skew
balanc
select
block
synthesi
activ
dendrit
cell
macrophag
polar
inflammatori
antiinflammatori
phenotyp
depend
microenvironment
stimuli
inhibit
activ
prolifer
independ
pathway
polar
macrophag
like
phenotyp
directli
act
cell
differenti
helper
cell
induc
regulatori
cell
maintain
express
key
transcript
factor
regulatori
cell
also
express
mice
defici
regulatori
cell
display
system
autoimmun
howev
mice
develop
spontan
coliti
skin
lung
hyperreact
suggest
organ
specif
role
regulatori
cell
although
often
associ
immun
suppress
function
recent
clinic
studi
unequivoc
shown
immun
activ
cytokin
promot
antitumor
immun
phase
clinic
trial
pegyl
recombin
human
shown
encourag
clinic
efficaci
sever
type
solid
tumor
among
patient
treat
monotherapi
activ
dose
overal
object
respons
rate
furthermor
treatment
increas
serum
level
proinflammatori
cytokin
well
fasl
cancer
patient
induc
cytokin
level
strongli
correl
clinic
respons
pegyl
treatment
dramat
expand
activ
cell
blood
cancer
patient
importantli
number
effector
function
til
patient
increas
result
support
major
function
expand
number
well
enhanc
effector
function
antitumor
cell
cancer
patient
phase
clinic
trial
patient
metastat
pancreat
cancer
conduct
base
promis
efficaci
data
earli
clinic
studi
mechanist
checkpoint
inhibit
treatment
togeth
enhanc
number
qualiti
preexist
til
efficaci
inhibitor
highli
associ
tumor
microenviron
til
densiti
express
tumor
intrins
featur
tumor
mutat
burden
microsatellit
instabl
well
gut
microbiota
clinic
trial
pegyl
recombin
human
focus
sever
solid
tumor
type
efficaci
solid
blood
tumor
type
need
test
clinic
futur
anoth
potenti
applic
antagonist
incorpor
vitro
expans
protocol
cell
act
primari
cytokin
use
vitro
expans
til
geneengin
cell
clinic
use
howev
vivo
efficaci
expand
cell
current
clinic
act
protocol
often
limit
ineffici
engraft
poor
persist
weak
capabl
attack
tumor
cell
shown
long
ago
augment
prolifer
promot
ctl
activ
activ
cell
consist
anim
studi
human
clinic
trial
data
show
promot
til
prolifer
addit
vitro
cultur
til
human
lung
cancer
drastic
enhanc
quantiti
qualiti
expand
human
til
upregul
gene
relat
sever
signal
pathway
tcr
signal
notch
signal
cell
cycl
ctl
kill
furthermor
pegyl
also
prevent
continu
tcrstimul
induc
apoptosi
activ
human
cell
interestingli
remiss
lymphoma
patient
treat
chimer
antigen
receptor
cart
cell
associ
high
serum
level
result
strongli
suggest
addit
vitro
cell
expans
protocol
may
improv
clinic
efficaci
adopt
cell
therapi
addit
antagonist
may
also
use
protocol
vitro
cultur
activ
cell
presenc
antagonist
induc
product
signific
progress
made
test
synergist
effect
combin
treatment
target
pathway
cancer
treatment
modal
first
combin
strategi
dual
blockad
complement
signal
immun
checkpoint
receptor
figur
complement
pathway
independ
pathway
modul
pathway
affect
express
cell
tumor
cell
two
differ
experiment
system
tumor
inocul
mice
tumorbear
wildtyp
mice
treat
antagonist
clearli
show
blockad
complement
signal
interact
dramat
synergist
antitumor
effect
synergist
antitumor
effect
subsequ
confirm
two
studi
data
provid
import
clue
ration
design
futur
clinic
trial
second
combin
treatment
strategi
use
complement
signal
blockad
chemotherapi
figur
squamou
cell
carcinoma
scc
model
antagonist
enhanc
treatment
efficaci
paclitaxel
chemotherapi
synergist
effect
depend
lymphocyt
increas
til
expans
specif
cell
clone
associ
enhanc
efficaci
third
combin
clinic
use
pegyl
antibodi
pembrolizumab
cohort
heavili
pretreat
patient
melanoma
nosquam
cell
lung
cancer
renal
cell
carcinoma
figur
combin
achiev
object
respons
rate
contrast
object
respons
rate
pegyl
monotherapi
combin
pegyl
promot
persist
prolifer
expans
cell
cancer
patient
excit
clinic
trial
result
open
new
avenu
effect
cancer
immunotherapi
summari
identifi
tumor
infiltr
cell
express
complement
receptor
complement
signal
inhibit
antitumor
function
repress
endogen
product
til
group
also
confirm
endogen
exogen
enhanc
antitumor
function
cell
human
mous
vitro
vivo
independ
signal
pathway
make
possibl
block
complement
receptor
combin
therapi
treat
cancer
patient
clinic
result
group
also
suggest
combin
blockad
complement
signal
antibodi
improv
efficaci
treatment
mechan
togeth
group
provid
clear
evid
complement
receptor
new
class
immun
checkpoint
receptor
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
